0JQ2.LKALA BIO, Inc.

About

Kala Bio, Inc. operates as a biopharmaceutical enterprise focused on developing and bringing to market innovative treatments. The company employs its unique, proprietary nanoparticle technology, designed to effectively penetrate mucus barriers. Initially, its efforts are concentrated on addressing various ocular conditions. Established in 2009 by founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, the firm maintains its headquarters in Arlington, Massachusetts.

www.kalarx.com

Key Statistics

Market Cap

254.16K

EPS

-165.50

Dividend Yield

0.00%

Beta

-2.41

P/B

0.64

Return on Equity

-385.6%

Sector

Healthcare

Industry

Biotechnology

CEO

Avi Minkowitz

Employees

38

IPO Date

2018-01-29

Country

US